Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
Other study identifiers
Sponsor study identifier
Secondary identifiers
observational
15
1 country
1
Study Start
May 18, 2011
Actual (reported)Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedBrief Summary
Background: \- Chronic infection with the hepatitis B virus may lead to cirrhosis, liver disease, and cancer of the liver. There is no cure for the infection, but several drugs have been approved to treat it. These drugs can keep the virus levels low. They seem to be safe for short-term use. But the drugs have not yet been approved for long-term use because some of them can have serious side effects. However, stopping treatment too soon can make the infection worse and may lead to more serious forms of liver disease. Researchers have not been able to determine a when to stop treatment. They want to study people with chronic hepatitis B infection to find out the best time to stop treatment and prevent the disease from causing further liver damage. Objectives:
- To study the safety and effectiveness of withdrawing antiviral treatment for chronic hepatitis B after at least 4 years of treatment.
- To determine whether stopping long-term antiviral treatment for chronic hepatitis B makes the infection worse. Eligibility: \- People who are at least 18 years of age; have been taking antiviral drugs to treat chronic hepatitis B for at least 4 years; and are being evaluated to stop treatment. Design:
- Those in the study will be screened with a physical exam, medical history, questionnaire, and blood tests. They will remain under the care of their regular doctor during the study.
- They will have an abdominal ultrasound to study scarring in the liver, if they have not had one in the past year.
- Those without detectable levels of the hepatitis B virus in their blood will stop antiviral treatment. They will have monthly blood tests for the first 6 months to check virus levels, and then every 3 months afterward.
- Those whose blood tests show an increase in virus levels will restart antiviral treatment as directed by the study doctors and their personal doctor.
- All those in the study will be monitored until the end of the study.
Registry Overview
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
- Recruitment status
- completed
- Actual enrollment (reported)
- 15 participants
- Study completion date
Not reported
Date not reported- Listed locations
- 1 countries · 1 sites
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
Study Start
May 18, 2011
Actual (reported)First Submitted
April 19, 2012
Actual (reported)First Posted
April 20, 2012
Actual (reported)
- Last Updated
- July 28, 2026
- Status Verified
- March 10, 2026
- Last Update Submitted
- July 25, 2026